𝔖 Bobbio Scriptorium

✦ LIBER ✦

Efficacy and safety of briakinumab in moderate to severe psoriasis patients with prior failure to TNF antagonist: Subanalysis of a 52-week phase III trial and open-label extension

Book ID: 116589009
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 47 KB
Volume: 66
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2011.11.803

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Short- and long-term briakinumab efficac

Short- and long-term briakinumab efficacy in moderate to severe psoriasis patients with prior TNF antagonist exposure: Subanalysis of a 52-week phase III trial and open-label extension

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Efficacy and safety of adalimumab in a 1

Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Efficacy and safety of briakinumab for t

Efficacy and safety of briakinumab for treatment of moderate to severe psoriasis in patients previously receiving etanercept: Results from an open-label extension

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy and safety results from a phase

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

✍ B.E. Strober; J.J. Crowley; P.S. Yamauchi; M. Olds; D.A. Williams 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

Efficacy and Safety of Efalizumab in Pat

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

✍ Torello Lotti; Sergio Chimenti; Andreas Katsambas; Jean-Paul Ortonne; Louis Dube 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

Efficacy and safety of efalizumab in adu

Efficacy and safety of efalizumab in adults with moderate to severe plaque psoriasis and hand and foot involvement: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 48 KB